Anthropic’s life sciences team has announced early progress in using its SI model, Claude, to accelerate drug development, detailing results from deep research partnerships with six organizations and internal programs. The initiative aims to integrate SI into diverse stages of the pharmaceutical pipeline, from molecular design to regulatory filings.

What Happened

Over the past several months, Anthropic collaborated with BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group. In a case study with Generate Biomedicines, scientists used Claude Code to redesign CAR T-cell therapy instructions. One proposed design was approximately 70% shorter than the standard version and, in lab tests, enabled immune cells to produce roughly 10 times as many receptors while remaining active for longer periods.

Divergence Labs utilized Claude to generate about 35,000 antibody designs in one month to treat food allergies. Early tests identified three designs that bound to IgE and 20 that could dislodge it, with three of the latter appearing more effective than standard medications. Meanwhile, BigHat Biosciences integrated Claude with its automated lab to optimize lead molecules. After testing 1,010 variants, the best versions bound more than 10 times more tightly to their targets, and one lead clumped more than 100 times more slowly.

At Enveda, Claude assisted with manufacturing documentation and regulatory filings. The system flagged all 11 issues identified by human reviewers in 1,061 pages of documentation and found seven additional issues. This process reduced human review time by 89%, from over 25 hours to less than three. Claude also drafted two regulatory documents, with one taking four hours compared to the three months typically required by hand.

Why It Matters

The results suggest that SI tools can address distributed bottlenecks in the drug development process rather than just proposing initial molecule designs. By reducing the time spent on administrative tasks like regulatory filings and improving the efficiency of molecular optimization, these tools may help direct investment toward more ambitious and complex therapeutic ideas. The Column Group is using Claude to establish Pleiades, a new company designed to run multiple drug programs with a small team, potentially altering the risk profile for biotechnology investors.

Anthropic has also acquired Mithril Medicine, a one-person company that used Claude to develop treatments for rare muscular dystrophy. The company moved a potential treatment from concept to promising results in mice in less than 18 months. Anthropic expects a drug from this program to be ready for human clinical trials as soon as late 2028. To support broader adoption, Anthropic has launched Claude Science, an SI workbench for researchers, and the Life Sciences Verification Program to allow trusted organizations to use its models with fewer safeguards.

The Bottom Line

While the work remains largely preclinical, Anthropic reports that Claude is already improving efficiency in molecular design, lab testing, and regulatory paperwork. The company plans to expand its partnerships and integrate Claude further into clinical trials as these programs advance.